The 1.15A crystal structure of the Staphylococcus aureus methionyl-aminopeptidase and complexes with triazole based

Christian Oefner1, Alice Douangamath, Allan D'Arcy

  • 1Morphochem AG, WRO-1055/338 Schwarzwaldallee 215, 4058 Basel, Switzerland.

Insights

Researchers discovered novel 1,2,4-triazole inhibitors for Staphylococcus aureus methionyl aminopeptidases (MetAP-I). These non-peptidic compounds show potential as antimicrobial agents by targeting essential bacterial enzymes.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Microbiology

Background:

  • Methionyl aminopeptidases (MetAPs) are crucial proteases removing N-terminal methionine from proteins.
  • MetAPs are classified into type I and type II, with eukaryotes having both and prokaryotes possessing only type I.
  • Inhibitors of MetAPs are of interest for antiangiogenic and antimicrobial applications.

Purpose of the Study:

  • To determine the high-resolution crystal structure of Staphylococcus aureus MetAP-I.
  • To investigate the binding of novel 1,2,4-triazole derivatives to MetAP-I.
  • To characterize a new class of non-peptidic MetAP inhibitors.

Main Methods:

  • X-ray crystallography was used to obtain the 1.15Å crystal structure of Staphylococcus aureus MetAP-I (apo-enzyme).
  • Complex structures of MetAP-I with various 1,2,4-triazole derivatives were determined.
  • Analysis of inhibitor binding within the enzyme's active site.

Main Results:

  • The crystal structure revealed a typical "pita-bread" fold for Staphylococcus aureus MetAP-I.
  • 1,2,4-triazole derivatives were observed to bind effectively in the active site.
  • The N1 and N2 atoms of the triazole moiety complexed with two divalent ions in the active site.

Conclusions:

  • 1,2,4-triazoles represent a novel class of potent, non-peptidic inhibitors for MetAP-I.
  • The structural data provides a basis for the rational design of new antimicrobial agents targeting bacterial MetAPs.
  • This study elucidates the mechanism of inhibition for this important class of enzymes.

Related Concept Videos

Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...